ENCell Co

ENCell Co Net Debt per Share

The Net Debt per Share of ENCell Co (456070.KQ) as of Oct 27, 2026 is 1,023.69 KRW. In the previous year, Net Debt per Share was -2,891.02 KRW — a change of -135.41% (higher).

Net Debt per Share

1,023.69KRW

YoY

-135.41%

Last updated:

Net Debt per Share of ENCell Co is 2025 1,023.69 KRW. Net Debt per Share of ENCell Co was 2024 -2,891.02 KRW. It decreases by -135.41% higher compared to the previous year.

The ENCell Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2021
2,570.29 KRW
Jan 1, 2022
-190.52 KRW
Jan 1, 2023
-1,622.70 KRW
Jan 1, 2024
-2,891.02 KRW
Jan 1, 2025
1,023.69 KRW
The ENCell Co Net Debt per Share history
YEARNet Debt per ShareYoY
1,023.69KRW-135.41%
-2,891.02KRW+78.16%
-1,622.70KRW+751.73%
-190.52KRW-107.41%
2,570.29KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ENCell Co Stock analysis

What does ENCell Co do? ENCell Co Ltd generates revenue through the development and research of cell and gene-based biopharmaceuticals, offering biopharmaceutical quality testing services, and providing biopharmaceutical consignment production. The company serves pharmaceutical and biotechnology firms requiring advanced drug development solutions and quality assurance. Its primary focus is on cell and gene therapies, with services tailored to support clients in the biopharmaceutical industry. The firm's offerings include research, testing, and production services for biopharmaceutical products. The company's core business model revolves around delivering specialized services to clients in the life sciences sector. It targets pharmaceutical companies and biotech firms seeking to develop and produce cell and gene-based treatments. ENCell's quality testing services ensure regulatory compliance and product safety, while its consignment production supports clients in scaling manufacturing without capital investment. These services collectively address key needs in the biopharmaceutical development lifecycle. ENCell Co Ltd's revenue streams are derived from research contracts, testing service fees, and consignment production agreements. The company's clients include pharmaceutical and biotechnology firms that outsource their biopharmaceutical development and production needs. By focusing on cell and gene-based therapies, ENCell positions itself as a specialized partner for clients navigating the complexities of modern biopharmaceutical innovation. ENCell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ENCell Co stock

Net Debt per Share of ENCell Co is 1,023.69 KRW in 2025.

Net Debt per Share of ENCell Co changed from -2,891.02 KRW to 1,023.69 KRW, representing a -135.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share ENCell Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — ENCell Co

All Key Metrics — ENCell Co